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Context: Plasma levels of C-reactive protein (CRP) are independently associated with risk of
coronary heart disease, but whether CRP is causally associated with coronary heart disease or
merely a marker of underlying atherosclerosis is uncertain.
Objective: To investigate association of genetic loci with CRP levels and risk of coronary heart
disease.
Design, setting and participants: We first carried out a genome-wide association (n=17,967)
and replication study (n=14,747) to identify genetic loci associated with plasma CRP
concentrations. Data collection took place between 1989 and 2008 and genotyping between 2003
and 2008. We carried out a Mendelian randomisation study of the most closely associated SNP in
the CRP locus and published data on other CRP variants involving a total of 28,112 cases and
100,823 controls, to investigate the association of CRP variants with coronary heart disease. We
compared our finding with that predicted from meta-analysis of observational studies of CRP
levels and risk of coronary heart disease. For the other loci associated with CRP levels, we
selected the most closely associated SNP for testing against coronary heart disease among 14,365
cases and 32,069 controls.
Main outcome measure: Risk of coronary heart disease.
Results: Polymorphisms in five genetic loci were strongly associated with CRP levels (%
difference per minor allele): SNP rs6700896 in LEPR (−14.7% [95% Confidence Interval {CI}],
−17.5 – −11.9, P=1.6×10−21), rs4537545 in IL6R (−10.8% [95% CI, −13.8 – −7.7], P=5.1×10−11),
rs7553007 in CRP locus (−20.7% [95% CI, −23.5 – −17.9], P=3.3×10−38), rs1183910 in HNF1A
(−13.6% [95% CI, −16.4 – −10.6], P=1.2×10−17) and rs4420638 in APOE-CI-CII (−21.8% [95%
CI, −25.4 – −18.1], P=2.1×10−25). Association of SNP rs7553007 in the CRP locus with coronary
heart disease gave odds ratio (OR) 0.98 (95% CI, 0.94 – 1.01) per 20% lower CRP. Our
Mendelian randomisation study of variants in the CRP locus showed no association with coronary
heart disease: OR 1.00 (95% CI, 0.97 – 1.02) per 20% lower CRP, compared with OR 0.94 (95%
CI, 0.94 – 0.95) predicted from meta-analysis of the observational studies of CRP levels and
coronary heart disease (Z-score −3.45, P<.001). SNPs rs6700896 in LEPR (OR 1.06 [95% CI,
1.02 – 1.09] per minor allele), rs4537545 in IL6R (OR 0.94 [95% CI, 0.91 – 0.97]) and rs4420638
in the APOE-CI-CII cluster (OR 1.16 [95% CI, 1.12 – 1.21]) were all associated with risk of
coronary heart disease.
Conclusions: The lack of concordance between the effect on coronary heart disease risk of CRP
genotypes and CRP levels argues against a causal association of CRP with coronary heart disease.
INTRODUCTION
Coronary heart disease (CHD) is the leading cause of death worldwide.1 Inflammation plays
a key role in the pathogenesis of CHD at every stage from initiation, to progression and
rupture of the atherosclerotic plaque.2 C-reactive protein (CRP), an acute phase protein
synthesised primarily by the liver, is currently the most widely used biomarker of
inflammation.3 Observational studies have consistently demonstrated that higher plasma
levels of CRP are associated with higher risk of CHD4,5, and measurement of CRP has been
advocated as a means of improving risk prediction.6 There is considerable interest in
establishing whether CRP has a causal role in CHD, or whether CRP is merely a marker of
underlying atherosclerosis.7,8 While previous studies have addressed this question, it is
unclear if they included a sufficient number of cases to have adequate statistical power to
confirm or refute associations of CHD with genetically determined differences in CRP
levels.8 Resolution of this question will improve understanding of inflammatory
mechanisms in atherosclerosis.
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The “Mendelian randomisation” concept has been used to investigate possible causal
relationships of an intermediate trait (such as CRP levels) with disease, taking advantage of
the random allocation of alleles at conception.9 If the intermediate trait is causally linked to
disease, then genetic variants influencing the trait should also influence disease risk.10
Mendelian randomisation studies should be unaffected by confounding from environmental
factors, e.g., smoking, and reverse causation bias, i.e., where the disease itself
(atherosclerosis) influences the trait (CRP levels).9
The aims of the present study were to conduct a genome-wide association study to identify
common genetic loci that influence CRP levels, and use the concept of Mendelian
randomisation to improve understanding of the possible causal relationship of CRP levels
with CHD.
DESIGN AND METHODS
Study design and rationale
The study involved four inter-related components:
i. a genome-wide association and replication study to identify genetic loci associated
with CRP levels, and at each locus, selection of the most closely associated SNP;
ii. a Mendelian randomisation study of CHD risk for the most associated SNP in the
CRP locus in our data, and published data on CRP variants, to assess the potential
causal association of CRP with CHD;
iii. comparison of the finding from the Mendelian randomisation study with that
predicted from meta-analysis of the relationship of CRP levels with CHD from
observational studies;
iv. a genetic association study of CHD for the most associated SNPs in genetic loci
outside the CRP locus, using the concept of CRP as an intermediate phenotype10 to
identify putative pathways linking inflammation with CHD.
Population cohorts
Genome-wide and replication study for CRP—Genome-wide association to identify
variants related to CRP levels, measured using high sensitivity assays, was carried out in
17,967 participants from five studies: the London Life Sciences Population study
(LOLIPOP: N=5,502), a population based cohort of European white and Indian Asian men
and women, aged 35-75 yrs, living in West London, UK11 (data collection 2001 – 2007,
genome-wide genotyping 2003 – 2008); the 1966 Northern Finnish Birth Cohort (NFBC:
N=4,761), a prospective birth cohort of persons born in 1966 in the two northernmost
provinces of Finland12,13 (data collection 1997 – 1998, genotyping 2007 – 2008); the
Lausanne Cohort (CoLaus: N=5,226), a cross-sectional study of a random sample of
European men and women, aged 35–75 yrs, living in Lausanne, Switzerland14 (data
collection 2003 – 2006, genotyping 2006 – 2007); the Genetic Epidemiology of Metabolic
Syndrome study (GEMS: N=1,781), a case-control study of dyslipidaemic cases (age 20–65
years) matched with normolipidaemic controls by sex and recruitment site15 (data collection
2003 – 2006, genotyping 2006 – 2007); and the Data from an Epidemiological Study on the
Insulin Resistance syndrome study (DESIR: N=697), a longitudinal French general
population cohort of persons aged 30-64 years recruited through the French social security
system16 (data collection 1994 – 2004, genotyping 2006 – 2007). Replication of SNPs
associated with CRP, identified in the genome-wide association study, was performed in a
further 14,747 LOLIPOP participants who were not included in the genome-wide
association study and were free of known CHD.
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Mendelian randomisation and genetic association studies with CHD—Variants
related to CRP were tested for association with CHD among 14,365 CHD cases and 32,069
controls. The participating studies comprised the Precocious Coronary Artery Disease study
(PROCARDIS: N=8,328), a case-control study of premature CHD before age 66 years17
(data collection 1999 – 2006, genotyping 2008); the International Studies of Infarct Survival
(ISIS: N=3,624), comprising men aged 30–54 yrs and women aged 30–64 yrs, with non-
fatal MI, and their spouse controls18,19 (data collection 1989 – 1992, genotyping 2008); the
British Heart Foundation Family Heart Study comprising individuals with myocardial
infarction or coronary revascularisation before the age of 66 years and at least one first-
degree relative with premature CHD, who were also studied as part of the Wellcome Trust
Case Control Consortium (WTCCC: N=3,249 to 4,863)20 (data collection 1998 – 2006,
genotyping 2006 – 2008); the German MI Family Studies (GerMIFS I): N=2,519; GerMIFS
II: N=2,520, comprising persons with myocardial infarction before the age of 60 years and
at least one first-degree relative with premature CHD, and matched controls20,21 (data
collection 1996 – 2008, genotyping 2006 – 2008); the INTERHEART study, a multinational
case-control study of persons presenting with first myocardial infarction (N=4,043)22, (data
collection 1999 – 2003, genotyping 2008); and the LOLIPOP study (N=20,475) (data
collection 2001 – 2007, genotyping 2008).
Genotyping
Genome-wide association scans were performed using the Affymetrix 500K mapping array,
the Illumina 317K array and Perlegen Sciences customised arrays. To combine data across
genotyping platforms, imputation was done using a Hidden Markov Model algorithm
implemented in MACH v1.0 software (Center for Statistical Genetics, University of
Michigan, MI, USA) (LOLIPOP) or IMPUTE v0.5.0 (Genetics Software Suite, University
of Oxford, UK) v0.5.0 (other studies), and phased haplotypes from HapMap build35, dbSNP
build 125. For the European datasets, the HapMap CEU sample was used for reference
haplotypes; Indian Asian datasets were imputed based on a combination (mixed) of HapMap
populations. Imputed SNPs with minor allele frequency (MAF)<.01, or low quality score
(r2<0.30 in MACH, or information score <0.5 in IMPUTE) were removed. This left ~1.4
million directly genotyped or imputed autosomal SNPs per participant with data available in
all samples. Genotyping for replication testing and for evaluation against CHD was
performed using KASPar (LOLIPOP), Sequenom (INTERHEART, PROCARDIS), TaqMan
(ISIS, WTCCC), or Affymetrix mapping arrays (GerMIFS1&2, WTCCC).
Statistical analyses
Genome-wide association and replication study for CRP—Genome-wide SNP
associations for CRP were tested in multiple linear regression analyses, using an additive
genetic model. CRP levels were log transformed to achieve approximate normal distribution,
and analysed as a quantitative trait with adjustment for age and sex (analysis of residuals
showed good adherence to normality assumptions). To account for heterogeneity in
population structure, principal components derived from EIGENSTRAT v2.0 (Reich Lab,
Harvard University, MA, USA) were included as covariates in age, sex adjusted analyses for
CoLaus, GEMs, NFBC, and LOLIPOP Indian Asian Illumina analyses (the number of
principal components included varied from 4 to 10, depending on the population structure of
the specific cohort). For other LOLIPOP data sets genomic control factors were used to
correct for any inflation. No principal components were included for DESIR as the
population was recruited from a geographically restricted area. Statistical software used for
genome-wide associations comprised SNPTEST (Genetics Software Suite, University of
Oxford, UK) v1.1.3 (DESIR), v1.1.4 (CoLaus, GEMS, NFBC); and MACH2QTL (Center
for Statistical Genetics, University of Michigan, MI, USA) v.1.0 (LOLIPOP). Results of the
separate genome-wide association studies were combined using weighted Z-scores, and a
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fixed rather than random effects model to maximise discovery, since random effects
estimates are associated with larger variance. QQ plots showed good adherence to null
expectations (Lambda for combined data = 1.0625). We used P<5×10−8 to designate
genome-wide significance, taking account of the ~ 1 million independent tests for common
variants across the genome.23 For five genetic loci associated with CRP at genome-wide
significance, we selected the single most closely associated SNP (i.e., smallest P-value) for
replication against CRP.
By use of QUANTO24 v1.2 for quantitative traits, we estimated that the genome-wide
association study had 80% power to detect SNPs associated with 0.2% of population
variation in CRP levels, or an 11% difference in CRP levels per allele copy, at MAF 30%
and genome-wide level of significance (P<5×10−8).
Mendelian randomisation study of genetic variants in the CRP locus and CHD
—We analysed relationship of dbSNP rs7553007 in the CRP locus, the SNP most strongly
associated with CRP levels in our data, for association with CHD risk using logistic
regression under an additive genetic model, as part of a Mendelian randomisation study. To
identify published data on the relationship of CRP variants with CHD, two electronic
databases (Medline and EMBASE) were searched up to and including November 2008 for
all prospective studies (including cohort, nested case-control and case-cohort studies), and
case-control studies, with no threshold sample size. For the search, the MeSH terms ‘C-
reactive protein’ and ‘polymorphism, single nucleotide’ or ‘polymorphism, genetic’ or
‘haplotype’ in combination with ‘coronary disease’ or ‘heart disease’, were used and the
search was limited by the terms ‘human’ and ‘English language’. We also scanned reference
lists of previous reports. Eight studies of 18 cohorts were identified examining. Two
studies25,26 examining nine cohorts reported results for a single SNP (dbSNP rs1130864);
for these studies, odds ratios (ORs) were reported under a recessive model comparing
homozygotes (TT) for the minor allele with CT/CC genotype, and mean effect on CRP was
obtained from published ratio of geometric means (1.21).25,26 For the remaining
studies8,27,28,29,30,31, we selected dbSNP rs1205 on the basis of MAF>0.1 and largest per
allele effect size on CRP levels (−0.35 mg/L) reported in the study of CRP variants and CRP
levels by Verzilli et al.32 We used per allele OR of rs1205 with CHD where available27,29
or where this could be estimated directly from the data8,31; otherwise ORs were estimated
from averaging published effect sizes for minor allele homozygotes (TT) and heterozygotes
(CT) compared to wild type (CC).28,30 We estimated standard errors of the effect sizes of
CRP variants on CHD from the reported 95% confidence intervals (CIs), assuming
normality. Estimated ORs for CRP variants on CHD were converted to a common scale by
standardising to 20% lower CRP, i.e., the approximate effect per minor allele of rs7553007
on CRP levels. Results were combined across studies by SNP, and across the three SNPs
weighted by the inverse of variance. We used 95% CIs and assessed heterogeneity with
standard χ2 statistics, expressed as I2, the proportion of variability between studies due to
heterogeneity.33 In the absence of heterogeneity, we used a fixed effects model.
We also investigated the three-way associations between CRP genetic variants, CRP levels,
and CHD in prospective studies which reported all three sets of data in the same
cohorts25,26,27,30; we did not include retrospective (case-control) studies since these could
be biased by treatment effects.34
Comparison of the result of the Mendelian randomisation study with meta-
analysis of the CRP-CHD relationship—We compared the result from our Mendelian
randomisation study with that predicted from a meta-analysis of the observational studies of
CRP levels and CHD.5,8,26,35,36,40,50-72 This was obtained from a systematic review of
the CRP-CHD relationship published by Shah et al.5, updated with all studies published
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from August 2007 until November 2008. For the search, the MeSH terms ‘C-reactive
protein’ and ‘CRP’ in combination with ‘coronary’, ‘coronary heart disease’, ‘CHD’ and
‘CVD’ were used, and the search was limited by the terms ‘human’ and ‘English language’.
Studies in which total mortality was the only outcome reported were excluded; if more than
one paper was published on the same cohort/ population the most recent one was used in the
meta-analysis. Five new population studies were identified from four reports.8,26,35,36
Risk ratios for CHD associated with CRP levels (logarithmically transformed) were
extracted from each study. Two studies were excluded: one37 which cited risk ratios per unit
increase in CRP (i.e., not logarithmically transformed) and one38 which did not provide CIs
for the association of CRP with CHD. The studies reported risk ratios based on different
comparisons of CRP (tertiles, quintiles, or quartiles), or as differences in risk for a given
increase in CRP; these were converted to common unit of 1 standard deviation (SD) change.
The risk ratio per SD change was converted to per 20% lower CRP by multiplying
coefficients (and 95% CIs) on the logarithmic scale by −0.223 assuming 20% reduction in
CRP is equivalent to a 0.223SD reduction in log CRP. Multivariate adjusted risk ratios,
controlled for conventional cardiovascular risk factors, were used when available; two
studies reported risk ratios adjusted for age, and age and smoking only.39,40 Because of
significant heterogeneity, random effects meta-analysis was used to combine the risk ratios
from the individual studies. The overall OR for CHD was used to test the observed vs.
predicted association of CRP variants with CHD, standardised to 20% lower CRP.
Genetic association of variants outside the CRP locus and CHD—The
relationships with risk of CHD of the most associated SNP in the four genetic loci other than
the CRP locus in our data, were analysed by logistic regression under an additive genetic
model. Results were combined across studies by SNP, using a fixed effects model weighted
by the inverse of variance, as there was no significant heterogeneity. By use of the Genetic
Power Calculator41, we estimated that the genetic association study with CHD had 80%
power to detect an OR of 1.04 per allele copy at P<0.05 and MAF 30%.
With the exception of the genome-wide association analyses described above, all statistical
analyses were done with STATA v10 (Statacorp LP, TX, USA). A significance level of
P<0.05 was used; all tests were two-sided.
Ethics approval was obtained locally for each of the participating cohorts for analyses of
genetic markers of cardiovascular disease risk. No additional ethics approvals were required
for this study.
RESULTS
Genome-wide association and replication study for CRP
We found 160 SNPs to be associated with CRP levels at P<5×10−8, distributed in the
following five loci: LEPR (GeneID 3953; GenBank NC_000001.9, region 65658906 to
65875410), IL6R (GeneID 3570, GenBank NC_000001.9, region 152644293 to
152706812), CRP (GeneID 1401, GenBank NC_000001.9, region 157951003 to
157948703), HNF1A (GeneID 6927, GenBank NC_ NC_000012.10, region 119900932 to
119924698) and APOE-CI-CII (GeneID 348, 341, 344, GenBank NC_000019.8, region
50100879 to 50104490). A Manhattan plot of results from the combined analysis of
genome-wide association data is shown in Figure 1. Genomic context and P-values for the
most associated SNP at each of the five loci are shown in Table 1. The association of these
SNPs with CRP was confirmed in replication testing (all P≤10−10); for all five SNPs, the
minor allele was associated with reduced levels of CRP (Table 1). For the most associated
SNP in the CRP locus (rs7553007), CRP levels were lower by 21% (95 % CI, −23.5–−17.9)
per minor allele. For the other four SNPs, per minor allele differences in CRP levels ranged
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from −10.8% (95% CI, −13.8–−7.7) for dbSNP rs4537545 in IL6R to −21.8% (95% CI,
−25.4–−18.1) for dbSNP rs4420638 in the APOECI-CII cluster (Table 1).
In the replication study (LOLIPOP), the percent variance of CRP explained ranged from
0.2% (dbSNP rs11839910 in HNF1A) to 1.3% (rs7553007 in the CRP locus). SNP
rs4420638 in the APOE-CI-CII cluster was strongly associated with total cholesterol (0.18
[95% CI, 0.13–0.22] mmol/L per minor allele), LDL cholesterol (0.16 [95% CI, 0.12–0.2]
mmol/L), triglycerides (0.11 [95% CI, 0.07–0.16] mmol/L) and HDL cholesterol (−0.03
[95% CI, −0.04–−0.02] mmol/L) (Table 2). SNP rs1183910 in HNF1A was also associated
with total cholesterol (0.03 [95% CI, 0.00–0.06] mmol/L per minor allele), LDL cholesterol
(0.03 [95% CI, 0.01–0.05] mmol/L) and HDL cholesterol (0.01 [95% CI, 0.00–0.02] mmol/
L). The remaining three SNPs were not significantly related to plasma lipids or with any of
the other phenotypes tested (Table 2).
Mendelian randomisation study of genetic variants in the CRP locus and CHD
Figure 2 shows the results of the Mendelian randomisation experiment of CHD with variants
in the CRP locus: SNP rs7553007 (our data) and published data for SNPs rs1130864 and
rs1205 for 18 cohorts. SNP rs7553007 was not significantly associated with CHD; estimated
OR was 0.98 (95% CI, 0.94-1.01) per 20% lower CRP. For rs1130864, OR was 1.00 (95%
CI, 0.86-1.15) and for rs1205, OR was 1.03 (95% CI, 0.99-1.07). There was no association
of CHD with CRP variants (per 20% lower CRP) when results for all three SNPs were
combined, OR 1.00 (95% CI, 0.97-1.02) (Figure 2).
In the three-way comparison of CRP genetic variants, CRP levels, and CHD risk reported in
prospective studies, there was significant association of CRP variants with CRP levels, CRP
levels with CHD, but not CRP variants with CHD (Figure 3).
Comparison of the result of the Mendelian randomisation study with meta-analysis of the
CRP-CHD relationship
The meta-analysis of observational studies of CRP levels and CHD gave a predicted OR
0.94 (95% CI, 0.94–0.95) per 20% lower CRP (Figure 4). This is significantly different to
the estimated effect on CHD (OR 1.00) of genetically determined differences in CRP levels
obtained from our Mendelian randomisation study (Z=−3.45, P<0.001).
Genetic association of variants outside the CRP locus and CHD
Minor alleles of dbSNP rs6700896 in LEPR and rs4420638 in APOE-CI-CII cluster were
associated with significantly increased risk of CHD (OR 1.06 [95% CI, 1.02–1.09] and 1.16
[95% CI, 1.12–1.21] respectively), SNP rs4537545 in IL6R with a decreased risk of CHD
(OR 0.94 [95% CI, 0.91, 0.97]), while SNP rs1183910 in HNF1A was not significantly
associated with CHD (Figure 5). The effects of SNPs rs6700896 in LEPR and rs4420638 in
the APOE-CI-CII cluster on CHD were in the opposite direction to that predicted from the
relationship of CRP levels with CHD (Figure 4); for rs4420638 the finding was consistent
with the effects on blood lipid concentrations (Table 2).
COMMENT
The present genome-wide association study confirms the associations of common genetic
variants in the LEPR, IL6R, CRP, HNF1A loci and APOE-CI-CII cluster with CRP levels.
42,43 However, minor allele of SNP rs7553007 and other variants in the CRP locus
included in our Mendelian randomisation study were not associated with CHD risk.
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The variants included in our Mendelian randomisation study are associated with ~20%
lower CRP levels32, corresponding to 6% reduction in CHD risk predicted by the meta-
analysis of observational studies of CHD risk in relation to differences in CRP levels. The
lack of association with CHD of genetic variants in the CRP locus suggests that the
observational data linking CRP levels and CHD may be confounded by association with
other CHD risk factors, or reflect a secondary inflammatory response associated with
atherosclerosis (‘reverse causation’), rather than indicating a causal relationship.
Our analysis of SNP rs7553007 with CHD risk includes more cases than all previously
published studies of CRP variants and CHD combined8,25,26,27,28,29,30,31, yielding a
total of over 28,000 cases and 100,000 controls for the Mendelian randomisation study. The
largest previous study, of three cohorts in Copenhagen, included 6,545 cases.8 In addition to
rs1205 included in our Mendelian randomisation study, it provides data on the tri-allelic
SNP rs3091244 and SNP rs3093077, both having variants with larger effects on CRP levels
(20-30%) than rs1205; however, both variants are rare, and neither was associated with
CHD in the Copenhagen study.8
The JUPITER trial recently reported a benefit of treatment with rosuvastatin on CHD risk
among men and women with elevated CRP levels (2.0 mg/L or higher) and with low-density
lipoprotein (LDL) cholesterol levels below 130 mg/dL (3.4 mmol/L).34 In the treatment
group, there was 54% reduction in rates of myocardial infarction compared with placebo;
LDL levels were reduced by 50% and CRP levels by 37%. Although the JUPITER trial
demonstrates the benefits of statin therapy in people with LDL levels below current
treatment threshold, the results may simply reflect the benefits of lipid-lowering therapy in
people who would not currently be considered for pharmacotherapy, rather than the benefits
of CRP-lowering per se.44
Investigation of genetic variants underlying an intermediate phenotype (such as CRP) has
been advocated as a means of discovering new disease susceptibility loci.10 In our study,
minor alleles of SNPs rs6700896 in LEPR and rs4420638 in the APOE-CI-CII cluster
showed significantly increased risk of CHD. However, both variants were associated with
reduced levels of CRP, suggesting that the links with CHD are not mediated by CRP. LEPR
has not previously been reported to increase risk of CHD, though associations of variants in
the APOE-CI-CII cluster with CHD have been observed.45,46 While the association of
genetic variation in APOE-CI-CII with CHD can be explained in large part by its effects on
blood lipids, this is not the case for SNP rs6700896 in LEPR, which was not associated with
major CHD risk factors. SNP rs6700896 is located in intron 19 of LEPR, the gene encoding
the leptin receptor, a member of the class I cytokine receptor family.47 LEPR is expressed
in the hypothalamus and vascular endothelial cells48, and LEPR signalling has a role in
appetite control, weight regulation, glucose homeostasis, blood pressure regulation and
angiogenesis.47,48,49 The minor allele of SNP rs4537545 in IL6R was also associated with
reduced CRP levels, and reduced risk of CHD. SNP rs4537545 in IL6R is in high LD (r2=
0.96 in the HapMap CEU reference population) with a non-synonymous SNP (rs8192284,
Asp358Ala) associated with increased IL6R expression, and alterations of IL6R membrane
binding50, providing a potential mechanism linking rs4537545 to biological function.
Further studies will be needed to confirm LEPR and IL6R as new susceptibility loci for
CHD.
Our study has limitations. Because of the relatively small effect of common genetic variants
in CRP locus on CRP levels, large sample size is needed to detect associations with CHD. In
order to combine data across studies in our Mendelian randomisation study, we assumed a
common effect on risk of CHD from different variants in the CRP locus, by standardising to
a common difference on the log CRP scale. This approach is valid to the extent that the
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hypothesised effect of CRP variants on CHD risk reflects circulating levels of CRP. Though
we found no association of CRP variants with CHD risk, it is not possible to exclude a small
effect, despite the large sample size. However, we can effectively exclude the size of
association predicted from observational data on the relationship of CRP levels to CHD. The
Mendelian randomisation approach makes a number of assumptions concerning possible
causality. These include the potential for pleiotropic effects of the genetic variants under
study (or variants in high LD with them) giving an alternative pathway to CHD, or
confounding through associations with disease risk factors.9 Neither rs7553007 or the other
two variants included from the CRP locus correlate with CHD risk factors8,26, satisfying an
important condition for a valid Mendelian randomisation experiment.9
In summary, our Mendelian randomisation study of over 28,000 cases and 100,000 controls
found no association of variants in the CRP locus and CHD, arguing against a causal role for
CRP in atherosclerosis. Moreover, this study suggests that development of therapeutic
strategies targeting specific reductions in plasma levels of CRP are unlikely to be fruitful.
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Figure 1.
Manhattan plot of results from the combined analysis of genome-wide association data (9
cohorts)
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Figure 2.
Results of Mendelian randomisation experiment of rs7553007 in the CRP locus (present
study), with rs1130864 and rs1205 from published studies, with CHD, among 28,112 cases
and 100,823 controls. Effects are given as Odds Ratios (95% Confidence Intervals) per 20%
lower CRP
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Figure 3.
Meta-analysis of associations of SNPs rs1130864 and rs1205 with CRP levels, CRP levels
with CHD, and SNPs with CHD, in prospective studies where all three analyses have been
reported. (a) Associations of SNPs rs1130864 and rs1205 with CRP levels. Effects are given
as % change (95% Confidence Intervals) per minor allele (rs1205) and per major allele
(rs1130864). (b) Associations of CRP levels with CHD. Effects are given as Odds Ratios
(95% Confidence Intervals) per 20% lower CRP. (c) Associations of SNPs rs1130864 and
rs1205 with CHD. Effects are given as Odds Ratios (95% Confidence Intervals) per 20%
lower CRP
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Figure 4.
Meta-analysis of the relationship of CRP levels with CHD from prospective observational
studies. Effects are given as Odds Ratios (95% Confidence Intervals) per 20% lower CRP
Footnote to Figure 4.
Random effects estimate presented in Figure, fixed effects estimate: OR 0.951 (95% CI,
0.945-0.957). For cohort studies, number of ‘controls’ represents the number of event-free
individuals. Number of controls was not available for ARIC (Ref 65).
*Case-cohort **Cohort ***Nested case-control
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Figure 5.
Associations of SNPs in LEPR (rs6700896), IL6R (rs4537545), HNF1A (rs1183910) loci
and APOE-CI-CII (rs4420638) cluster in the genetic association study with CHD. Effects
are given as Odds Ratios (95% Confidence Intervals) per copy of minor allele
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